Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1991 May;54(5):401–405. doi: 10.1136/jnnp.54.5.401

Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.

M M Mouradian 1, I J Heuser 1, F Baronti 1, M Giuffra 1, K Conant 1, T L Davis 1, T N Chase 1
PMCID: PMC488537  PMID: 1865201

Abstract

Direct acting dopamine agonists are generally less effective than levodopa in relieving symptoms of Parkinson's disease. In an attempt to quantitate and explain this situation, the acute motor responses to intravenous injections of the dopamine agonist, (-)-N-n-propyl-norapomorphine hydrochloride (NPA), were compared with those of the dopamine precursor, levodopa. At optimum dose levels, the acute anti-Parkinsonian efficacy of NPA averaged only about 50% of maximum, while essentially total symptom suppression was obtained with levodopa in patients previously treated with the amine precursor. Dyskinesia severity, however, was similar with the two drugs. These differences in anti-Parkinsonian efficacy may reflect the fact that while NPA acts mainly on D-2 dopamine receptors, levodopa results in stimulation of both the D-1 and D-2 subsets of receptors at a more physiological ratio. Future efforts to develop dopamine agonists for the treatment of Parkinsonian symptoms may thus have to consider focusing on drugs having pharmacological profile more similar to that of dopamine.

Full text

PDF
401

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen P. H. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol. 1988 Jan 27;146(1):113–120. doi: 10.1016/0014-2999(88)90492-x. [DOI] [PubMed] [Google Scholar]
  2. Arnt J., Bøgesø K. P., Hyttel J., Meier E. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol Toxicol. 1988 Mar;62(3):121–130. doi: 10.1111/j.1600-0773.1988.tb01859.x. [DOI] [PubMed] [Google Scholar]
  3. Braun A. R., Chase T. N. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol. 1986 Nov 19;131(2-3):301–306. doi: 10.1016/0014-2999(86)90588-1. [DOI] [PubMed] [Google Scholar]
  4. Bunzow J. R., Van Tol H. H., Grandy D. K., Albert P., Salon J., Christie M., Machida C. A., Neve K. A., Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature. 1988 Dec 22;336(6201):783–787. doi: 10.1038/336783a0. [DOI] [PubMed] [Google Scholar]
  5. Critchley P., Langdon N., Parkes J. D., Quinn N. P., Shindler J. S., Marsden C. D. Domperidone. Br Med J (Clin Res Ed) 1985 Mar 9;290(6470):788–788. doi: 10.1136/bmj.290.6470.788-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crossman A. R. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord. 1990;5(2):100–108. doi: 10.1002/mds.870050203. [DOI] [PubMed] [Google Scholar]
  7. Fahn S. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology. 1974 May;24(5):431–441. doi: 10.1212/wnl.24.5.431. [DOI] [PubMed] [Google Scholar]
  8. Grandas F., Obeso J. A. Motor response following repeated apomorphine administration is reduced in Parkinson's disease. Clin Neuropharmacol. 1989 Feb;12(1):14–22. doi: 10.1097/00002826-198902000-00002. [DOI] [PubMed] [Google Scholar]
  9. Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology. 1985 Mar;35(3):296–299. doi: 10.1212/wnl.35.3.296. [DOI] [PubMed] [Google Scholar]
  10. Javoy-Agid F., Ruberg M., Taquet H., Bokobza B., Agid Y., Gaspar P., Berger B., N'Guyen-Legros J., Alvarez C., Gray F. Biochemical neuropathology of Parkinson's disease. Adv Neurol. 1984;40:189–198. [PubMed] [Google Scholar]
  11. Lang A. E. Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine". Can J Neurol Sci. 1987 Aug;14(3 Suppl):474–482. doi: 10.1017/s031716710003794x. [DOI] [PubMed] [Google Scholar]
  12. Larsen T. A., Newman R., LeWitt P., Calne D. B. Severity of Parkinson's disease and the dosage of bromocriptine. Neurology. 1984 Jun;34(6):795–797. doi: 10.1212/wnl.34.6.795. [DOI] [PubMed] [Google Scholar]
  13. LeWitt P. A., Ward C. D., Larsen T. A., Raphaelson M. I., Newman R. P., Foster N., Dambrosia J. M., Calne D. B. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology. 1983 Aug;33(8):1009–1014. doi: 10.1212/wnl.33.8.1009. [DOI] [PubMed] [Google Scholar]
  14. Lees A. J., Stern G. M. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1981 Nov;44(11):1020–1023. doi: 10.1136/jnnp.44.11.1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  16. Marsden C. D., Parkes J. D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977 Feb 12;1(8007):345–349. doi: 10.1016/s0140-6736(77)91146-1. [DOI] [PubMed] [Google Scholar]
  17. Menon M. K., Clark W. G., Neumeyer J. L. Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine. Eur J Pharmacol. 1978 Nov 1;52(1):1–9. doi: 10.1016/0014-2999(78)90015-8. [DOI] [PubMed] [Google Scholar]
  18. Mouradian M. M., Juncos J. L., Fabbrini G., Schlegel J., Bartko J. J., Chase T. N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol. 1988 Sep;24(3):372–378. doi: 10.1002/ana.410240304. [DOI] [PubMed] [Google Scholar]
  19. O'Connell J. E. Craniopagus twins: surgical anatomy and embryology and their implications. J Neurol Neurosurg Psychiatry. 1976 Jan;39(1):1–22. doi: 10.1136/jnnp.39.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Obeso J. A., Luquin M. R., Martínez Lage J. M. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease. Ann Neurol. 1986 Jan;19(1):31–35. doi: 10.1002/ana.410190107. [DOI] [PubMed] [Google Scholar]
  22. Parkes J. D. Domperidone and Parkinson's disease. Clin Neuropharmacol. 1986;9(6):517–532. doi: 10.1097/00002826-198612000-00003. [DOI] [PubMed] [Google Scholar]
  23. Rascol A., Guiraud B., Montastruc J. L., David J., Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry. 1979 Feb;42(2):143–150. doi: 10.1136/jnnp.42.2.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Reisine T. D., Fields J. Z., Yamamura H. I. Neurotransmitter receptor alterations in Parkinson's disease. Life Sci. 1977 Aug 1;21(3):335–343. doi: 10.1016/0024-3205(77)90514-8. [DOI] [PubMed] [Google Scholar]
  25. Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology. 1987 May;37(5):826–828. doi: 10.1212/wnl.37.5.826. [DOI] [PubMed] [Google Scholar]
  26. Staal-Schreinemachers A. L., Wesseling H., Kamphuis D. J., vd Burg W., Lakke J. P. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology. 1986 Feb;36(2):291–293. doi: 10.1212/wnl.36.2.291. [DOI] [PubMed] [Google Scholar]
  27. Stibe C. M., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988 Feb 20;1(8582):403–406. doi: 10.1016/s0140-6736(88)91193-2. [DOI] [PubMed] [Google Scholar]
  28. Temlett J. A., Quinn N. P., Jenner P. G., Marsden C. D., Pourcher E., Bonnet A. M., Agid Y., Markstein R., Lataste X. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov Disord. 1989;4(3):261–265. doi: 10.1002/mds.870040307. [DOI] [PubMed] [Google Scholar]
  29. Uhl G. R., Hackney G. O., Torchia M., Stranov V., Tourtellotte W. W., Whitehouse P. J., Tran V., Strittmatter S. Parkinson's disease: nigral receptor changes support peptidergic role in nigrostriatal modulation. Ann Neurol. 1986 Aug;20(2):194–203. doi: 10.1002/ana.410200204. [DOI] [PubMed] [Google Scholar]
  30. Walters J. R., Bergstrom D. A., Carlson J. H., Chase T. N., Braun A. R. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science. 1987 May 8;236(4802):719–722. doi: 10.1126/science.2953072. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES